Navigation Links
Cancer Immunotherapy Expert Joins Pacific Meso Center Research Team
Date:6/8/2012

LOS ANGELES, June 8, 2012 /PRNewswire/ -- The Pacific Meso Center (PMC) announces the appointment of its new scientific researcher for its laboratory on Santa Monica Boulevard. A graduate of the University of Southern California, Dr. Raymond M. Wong, Ph.D. joins the center after 5 years with MannKind Corporation, where he worked in cancer immunotherapy and specifically on preclinical development for MannKind's MKC-1106-MT and MKC-1106-PP cancer vaccine programs.

At PMC, Dr. Wong, who has a Ph.D. in immunology and whose work has been published in many scientific journals, will be responsible for planning and conducting the research on malignant pleural mesothelioma, an asbestos-related cancer affecting the pleura - the lining of the chest cavity. Dr. Robert B. Cameron, M.D., scientific advisor at PMC, stated, "Dr. Wong comes highly recommended and is an outstanding scientist with the research knowledge in immunology and immunotherapy who will help PMC develop promising immunotherapy treatments for mesothelioma patients at a time when immunotherapy has again become a focus of research for many cancers. He will be collaborating with Dr. Dongmei Hou of the Punch Worthington Research Laboratory at UCLA and with Dr. Saroj Basak of the Veterans Administration Medical Center in West Los Angeles." 

Dr. Wong also will collaborate with PMC's Scientific Advisor, Dr. Robert B. Cameron, who is a board certified cardiothoracic surgeon and surgical oncologist, the director of the UCLA Comprehensive Mesothelioma Program at the David Geffen School of Medicine at UCLA, Chief of Thoracic Surgery at the West Los Angeles Veterans Administration Medical Center, and a long-time proponent of lung-sparing surgery for malignant pleural mesothelioma. Together Drs. Wong and Cameron will work to advance therapeutic cancer immunotherapy strategies from pre-clinical stages to phase I/II clinical trials.

About Pacific Meso Center

The Pacific Meso Center (PMC), a division of The Pacific Heart, Lung & Blood Institute, was established in 2002 with the goal of becoming the most innovative research and treatment organization in the world for patients with malignant pleural mesothelioma (MPM), a rare form of cancer related to asbestos exposure. PMC focuses on specific areas of research that improve mesothelioma victims' lives and longevity, particularly those promising treatments that approach MPM as a chronic, treatable disease. The ultimate goal of PMC is finding a cure for mesothelioma.

For further information, please contact:

Clare Cameron
The Pacific Meso Center
310-478-4678
ccameron@phlbi.org
http://www.pacificmesocenter.org          

 

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.

 


'/>"/>
SOURCE The Pacific Meso Center
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
2. Virobays Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
3. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
4. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
5. Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer
6. Masaryk Memorial Cancer Institute Reduces Losses and Administrative Overhead With Ekahau RTLS
7. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
8. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
9. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
10. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
11. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Boston, MA (PRWEB) , ... April 28, 2016 ... ... (EDT), Asymmetrex will deliver a talk on its first-in-class technologies for ... the 2016 Meeting on RNAiMicroRNA Biology to Reprogramming & CRISPR-based Genome ...
(Date:4/27/2016)... ... ... Cambridge Semantics, the leading provider of Smart Data analytic and ... named to The Silicon Review’s “20 Fastest Growing Big Data Companies of 2016.” ... needs of end users facing some of the most complex data challenges in the ...
(Date:4/27/2016)... ... April 27, 2016 , ... Most consumers engage ... fingerprint recognition for secure access, voice recognition for hands-free communication, and facial recognition ... interacting with biometrics technology today. But if they asked Joey Pritikin, Vice ...
(Date:4/27/2016)... British Virgin Islands (PRWEB) , ... April 27, ... ... Holding Company Ltd. (d/b/a Biohaven) is pleased to announce the appointment of John Tilton ... he was an Executive Director and one of the founding commercial leaders responsible ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/19/2016)... April 20, 2016 The new ... a compact web-based "all-in-one" system solution for all door ... reader or the door interface with integration authorization management ... control systems. The minimal dimensions of the access control ... the building installations offer considerable freedom of design with ...
(Date:4/14/2016)... TEL AVIV, Israel , April 14, 2016 /PRNewswire/ ... in Behavioral Authentication and Malware Detection, today announced the ... has already assumed the new role. Goldwerger,s ... for BioCatch, on the heels of the deployment of ... In addition, BioCatch,s behavioral biometric technology, which discerns unique ...
Breaking Biology News(10 mins):